+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of elismetrep, compared with placebo, for treating moderate to severe migraine in adults. This randomized, double-blind, multicenter outpatient study focuses on patients aged 18 to 75 who experience frequent migraine attacks. The trial aims to better understand elismetreps impact on migraine symptoms and relief. Participants are randomly assigned to receive a single oral dose of either elismetrep 10 mg, elismetrep 20 mg, or placebo. The study is conducted in a parallel design with triple masking to reduce bias. The primary focus is on pain freedom and relief from the most bothersome migraine symptoms within two hours after dosing. During the trial, participants will report their migraine symptoms and responses to treatment using study questionnaires and an electronic diary. Researchers will assess outcomes such as pain relief at 2 hours, sustained pain freedom up to 48 hours, freedom from nausea, photophobia, and phonophobia, and the need for rescue medication. Safety is monitored through adverse event reporting up to 8 days post-dose. The study is expected to last until December 2027.

Age: 18Years - 75YearsAll GendersPhase 3
72 locations
S

Actively Recruiting

Researchers are evaluating the safety and tolerability of taking an additional dose of the medicine rimegepant for adults with migraine who may not get full pain relief from the first dose. The study focuses on people aged 18 or older with a history of migraine and examines whether a second dose within 24 hours can help manage migraine attacks better. This research is a Phase 4, open-label trial sponsored by Pfizer, aiming to understand the effects of redosing rimegepant for acute migraine treatment. Participants will take rimegepant 75 mg orally disintegrating tablet ODT to treat moderate or severe migraine attacks. If they are not pain-free about 2 hours after the first dose or experience headache relapse after initial relief, they may take a second dose within 24 hours. This redosing can occur up to 10 times per month over a 24-week open-label treatment phase. During the study, participants will be monitored for treatment-emergent adverse events and liver function test changes related to redosing frequency. Satisfaction with headache pain reduction and impact on daily activities will also be assessed. The study involves regular evaluation over up to 6 months to measure tolerability, safety, and participant-reported outcomes while using rimegepant for acute migraine attacks.

Age: 18Years +All GendersPhase 4
24 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.

Age: 16Years - 80YearsAll GendersPhase 3
461 locations
P

Actively Recruiting

Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.

Age: 16Years - 80YearsAll GendersPhase 3
240 locations
V

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Dozee VS system, a contactless device designed to monitor heart rate and breathing rate using a sensor sheet placed under the mattress. This device captures body vibrations and converts them into vital signs, which can be monitored remotely in real time. The study aims to validate updated AI-powered heart rate and breathing rate algorithms across different sensor sheet types to confirm their clinical accuracy compared to gold standard methods. The Dozee VS system includes a thin sensor sheet that detects small vibrations from the heart and lungs. It connects to an online dashboard for real-time monitoring and supports additional devices like a blood pressure cuff, pulse oximeter, and thermometer. The study compares the new AIML-based heart rate algorithm and improved breathing rate algorithm performance across three sensor sheet types DS, S1, and S1-I while participants also undergo standard telemetry monitoring using electrocardiography and capnography. Participants will be monitored simultaneously with the Dozee device and standard telemetry devices during their hospital stay. Data on heart rate and respiratory rate will be collected continuously for up to six months. Researchers will measure the mean absolute error of the Dozee devices readings compared to the gold standard methods to assess accuracy. The study lasts up to six months, with no invasive procedures required, and participants provide informed consent before enrollment.

Age: 22Years - 100YearsAll Genders
1 location
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of rimegepant compared to a placebo as a preventative treatment for children and adolescents aged 6 to under 18 years with episodic migraine. The study focuses on reducing the number of migraine days per month and improving quality of life in this young population. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Pfizer. Participants receive either rimegepant in doses of 75mg or 50mg two 25mg orally disintegrating tablets or a matching placebo with the same dosing options. The study uses a double-blind design over a 12-week treatment phase to compare outcomes. The research also monitors safety and tolerability for up to 72 weeks, including the frequency of liver-related adverse events. During the study, participants will have assessments to record migraine days and severity, use of acute migraine medications, and quality of life using the Pediatric Quality of Life Inventory. Researchers will track safety through ongoing monitoring for adverse effects. The primary measure is the change in mean monthly migraine days over 12 weeks, with additional evaluations during the first 4 weeks and longer-term safety follow-up. Total participation may last up to 72 weeks for safety evaluation.

Age: 6Years - 17YearsAll GendersPhase 3
93 locations